The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 23 March 2026•Updated 25 March 2026•

1 min read

Apogee Therapeutics Upsizes Public Offering to $350 Million at $70 Per Share

Key Facts

1Apogee Therapeutics announced the commencement of an underwritten public offering of $300 million of its common stock.

2 months ago

Version History

4 additional sources confirmed this story

Version 12 months ago

What changed: The offering size was upsized to $350 million from $300 million, the share price was finalized at $70.00, and the closing date was set.

Apogee Therapeutics, Inc. (Nasdaq: APGE) has priced its upsized public offering of common stock at $70.00 per share, raising the total expected gross proceeds to $350 million from the previously announced $300 million. The offering consists of 5,000,000 shares of common stock, with underwriters granted a 30-day option to purchase an additional 750,000 shares. This clinical-stage biotechnology firm intends to use the capital to advance its pipeline of biologics for inflammatory and immunology (I&I) markets and for general corporate purposes. The offering is scheduled to close on March 26, 2026, subject to customary closing conditions. While the increased capital provides a stronger financial cushion for research and development, the market is assessing the potential for equity dilution. Investors are closely watching APGE's performance on the Nasdaq as the market absorbs the increased supply of shares.